Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.36 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31341213 | 0.89 | CTSK (0.43) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18109360 | 0.88 | CTSK (0.43) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24324050 | 0.88 | CTSK (0.43) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18109361 | 0.88 | CTSK (0.43) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30365328 | 0.87 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24299005 | 0.86 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6354784 | 0.86 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31341192 | 0.84 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25464726 | 0.83 | CTSK (0.39) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25464692 | 0.83 | CTSK (0.39) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688156-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-26 | — | — | US | disclosed |
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-03 | — | — | US | disclosed |
| US-12215111-B2 | Imidazopyridazine IL-17 inhibitor compounds | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-04 | — | — | US | disclosed |
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-24 | — | — | US | disclosed |
| WO-2024201322-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408529-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408847-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023049887-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049886-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CTSK 3226/4885CTSS 3561/4885CYP1A2 114/4885 |
| US-12173007-B2 | Imidazopyridazine IL-17 inhibitor compounds | IL17A, IL23R, IL15 | CTSK 3226/4885CTSS 3561/4885CYP1A2 114/4885 |
| US-20230143050-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CTSK 3226/4885CTSS 3561/4885CYP1A2 114/4885 |
| US-20250109137-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CTSK 3226/4885CTSS 3561/4885CYP1A2 114/4885 |
| US-12215111-B2 | Imidazopyridazine IL-17 inhibitor compounds | IL17A, IL23R, IL15 | CTSK 3226/4885CTSS 3561/4885CYP1A2 114/4885 |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | CTSK 3226/4885CTSS 3561/4885CYP1A2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.